Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer

NCT02288936 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

98

Enrollment

OTHER

Sponsor class

Conditions

Hormone-refractory Prostate Cancer

Interventions

DRUG: Enzalutamide

Sponsor

Spanish Oncology Genito-Urinary Group

Collaborators

[object Object]
[object Object]